TXNL1

Summary

TXNL1 (thioredoxin like 1, HGNC:12436) is a protein-coding gene on chromosome 18q21.31, encoding Thioredoxin-like protein 1 (O43396). Active thioredoxin with a redox potential of about -250 mV.

Enables disulfide oxidoreductase activity. Located in cytosol.

Source: NCBI Gene 9352 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 41 total
• Druggable target: yes
• MANE Select transcript: NM_004786

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12436
Approved symbol	TXNL1
Name	thioredoxin like 1
Location	18q21.31
Locus type	gene with protein product
Status	Approved
Aliases	Txl, TRP32
Ensembl gene	ENSG00000091164
Ensembl biotype	protein_coding
OMIM	603049
Entrez	9352

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 16 protein_coding, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000217515, ENST00000585497, ENST00000586079, ENST00000586262, ENST00000587613, ENST00000587807, ENST00000588615, ENST00000589329, ENST00000589415, ENST00000589931, ENST00000590954, ENST00000857333, ENST00000857334, ENST00000857335, ENST00000857336, ENST00000857338, ENST00000939690, ENST00000939691, ENST00000939692, ENST00000939693, ENST00000939694

RefSeq mRNA: 1 — MANE Select: NM_004786 NM_004786

CCDS: CCDS11961

Canonical transcript exons

ENST00000217515 — 8 exons

Exon	Start	End
ENSE00001106452	56597209	56603056
ENSE00001252552	56638343	56638592
ENSE00003479523	56626361	56626457
ENSE00003505098	56616245	56616314
ENSE00003521487	56618004	56618126
ENSE00003607270	56614424	56614596
ENSE00003659882	56610993	56611097
ENSE00003678911	56624288	56624461

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 99.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 83.7246 / max 618.7786, expressed in 1827 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
172092	76.8856	1827
172093	4.3979	1568
172094	2.1178	1292
172095	0.3234	166

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	99.25	gold quality
cervix squamous epithelium	UBERON:0006922	99.10	gold quality
endothelial cell	CL:0000115	99.02	gold quality
hair follicle	UBERON:0002073	98.99	gold quality
oral cavity	UBERON:0000167	98.71	gold quality
heart right ventricle	UBERON:0002080	98.71	gold quality
trabecular bone tissue	UBERON:0002483	98.66	gold quality
biceps brachii	UBERON:0001507	98.57	gold quality
pigmented layer of retina	UBERON:0001782	98.56	gold quality
choroid plexus epithelium	UBERON:0003911	98.56	gold quality
middle temporal gyrus	UBERON:0002771	98.54	gold quality
sperm	CL:0000019	98.41	gold quality
right lobe of thyroid gland	UBERON:0001119	98.39	gold quality
male germ cell	CL:0000015	98.38	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.35	gold quality
thyroid gland	UBERON:0002046	98.28	gold quality
left lobe of thyroid gland	UBERON:0001120	98.27	gold quality
mucosa of sigmoid colon	UBERON:0004993	98.22	gold quality
tongue squamous epithelium	UBERON:0006919	98.19	gold quality
corpus epididymis	UBERON:0004359	98.12	gold quality
squamous epithelium	UBERON:0006914	98.11	gold quality
epithelium of nasopharynx	UBERON:0001951	98.09	gold quality
jejunal mucosa	UBERON:0000399	98.08	gold quality
germinal epithelium of ovary	UBERON:0001304	98.08	gold quality
gastrocnemius	UBERON:0001388	98.07	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.05	gold quality
cortical plate	UBERON:0005343	98.04	gold quality
seminal vesicle	UBERON:0000998	98.01	gold quality
colonic mucosa	UBERON:0000317	97.99	gold quality
gingival epithelium	UBERON:0001949	97.98	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7052	yes	627.89
E-GEOD-124858	no	599.25
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting TXNL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-1825	99.72	68.11	1089
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-4470	99.66	69.35	1767
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-4666B	99.64	68.69	1282
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-199A-5P	99.51	69.71	1107
HSA-MIR-199B-5P	99.51	69.74	1098
HSA-MIR-7849-3P	99.47	68.17	1224
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-580-5P	99.28	70.94	1776
HSA-MIR-3191-5P	99.24	66.52	1722
HSA-MIR-593-3P	99.22	67.28	1327
HSA-MIR-100-3P	99.20	67.33	672
HSA-MIR-3164	99.02	68.39	1071
HSA-MIR-6820-3P	99.02	68.50	1035
HSA-MIR-3908	98.75	67.31	1160
HSA-MIR-198	98.70	67.32	920
HSA-MIR-665	97.60	65.64	1781
HSA-MIR-3139	96.68	66.77	652
HSA-MIR-592	96.59	67.59	817
HSA-MIR-410-5P	96.55	66.28	459

Literature-anchored findings (GeneRIF, showing 9)

• results imply that TRP-1 is a mammalian thioredoxin and plays as a transcriptional repressor through direct binding to the transcription factor B-Myb (PMID:16231315)
• TXNL1 acts as an effector of oxidants or a redox sensor by converting redox changes into changes of GDI capacity to capture Rab5, which in turn modulates fluid phase endocytosis (PMID:17987124)
• Txnl1 is the first example of a direct connection between protein reduction and proteolysis, two major intracellular protein quality control mechanisms. (PMID:19349277)
• TRP32 was identified as a novel subunit of the 26 S proteasome. (PMID:19349280)
• Solution structure of the C-terminal DUF1000 domain of the human thioredoxin-like 1 protein. (PMID:20455272)
• Distinct protein expression patterns, affecting TXNL1 and HDAC2, distinguish aneuploid with poor prognosis from diploid colorectal cancers. (PMID:21290163)
• Results suggest that TRP32 maintains the reduced state of PRL and thus regulates the biological function of PRL. (PMID:23362275)
• TXNL1 is a novel regulatory molecule that inhibits cisplatin resistance in gastric cancer cells. (PMID:24525731)
• TXNL1-XRCC1 is a novel regulatory pathway that has an independent role in cisplatin resistance, indicating a putative drug target for reversing cisplatin resistance in gastric cancer. (PMID:24525731)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	txnl1	ENSDARG00000011921
mus_musculus	Txnl1	ENSMUSG00000024583
rattus_norvegicus	Txnl1	ENSRNOG00000018818
drosophila_melanogaster	Txl	FBGN0035631
caenorhabditis_elegans	txl-1	WBGENE00021826

Paralogs (4): TXN2 (ENSG00000100348), TXN (ENSG00000136810), TXNDC2 (ENSG00000168454), TXNDC8 (ENSG00000204193)

Protein

Protein identifiers

Thioredoxin-like protein 1 — O43396 (reviewed: O43396)

Alternative names: 32 kDa thioredoxin-related protein

All UniProt accessions (7): O43396, K7EKG2, K7EME7, K7EML9, K7EPB7, K7ER96, V9HW51

UniProt curated annotations — full annotation on UniProt →

Function. Active thioredoxin with a redox potential of about -250 mV.

Subunit / interactions. Component of the 19S regulatory cap of the 26S proteasome. Interacts with PSMD14/RPN11. Interacts with, and reduces EEF1A1.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Ubiquitous.

RefSeq proteins (1): NP_004777* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008979	Galactose-bd-like_sf	Homologous_superfamily
IPR010400	PITH_dom	Domain
IPR013766	Thioredoxin_domain	Domain
IPR017937	Thioredoxin_CS	Conserved_site
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR037047	PITH_dom_sf	Homologous_superfamily

Pfam: PF00085, PF06201

UniProt features (38 total): strand 17, helix 9, turn 6, domain 2, initiator methionine 1, chain 1, modified residue 1, disulfide bond 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
1GH2	X-RAY DIFFRACTION	2.22
9E8I	ELECTRON MICROSCOPY	2.87
9E8H	ELECTRON MICROSCOPY	2.9
9E8G	ELECTRON MICROSCOPY	3.01
9E8O	ELECTRON MICROSCOPY	3.1
9BW4	ELECTRON MICROSCOPY	3.3
9E8J	ELECTRON MICROSCOPY	3.47
9E8L	ELECTRON MICROSCOPY	3.59
9E8N	ELECTRON MICROSCOPY	3.62
9E8K	ELECTRON MICROSCOPY	4.08
1WWY	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43396-F1	91.66	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 113

Disulfide bonds (1): 34–37

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-9013418	RHOBTB2 GTPase cycle
R-HSA-9013420	RHOU GTPase cycle
R-HSA-9013422	RHOBTB1 GTPase cycle
R-HSA-9013424	RHOV GTPase cycle
R-HSA-9696264	RND3 GTPase cycle
R-HSA-9696270	RND2 GTPase cycle
R-HSA-9696273	RND1 GTPase cycle

MSigDB gene sets: 160 (showing top): GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, RIZKI_TUMOR_INVASIVENESS_3D_DN, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GROSS_HYPOXIA_VIA_ELK3_DN, AAAGACA_MIR511, STONER_ESOPHAGEAL_CARCINOGENESIS_UP, DING_LUNG_CANCER_EXPRESSION_BY_COPY_NUMBER, NOUZOVA_TRETINOIN_AND_H4_ACETYLATION, ACEVEDO_LIVER_CANCER_UP, AGCTCCT_MIR28, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, MARSON_BOUND_BY_E2F4_UNSTIMULATED, MODULE_363, SANSOM_APC_TARGETS, GOMF_DISULFIDE_OXIDOREDUCTASE_ACTIVITY

GO Biological Process (0):

GO Molecular Function (2): protein-disulfide reductase activity (GO:0015035), disulfide oxidoreductase activity (GO:0015036)

GO Cellular Component (4): proteasome complex (GO:0000502), nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RHO GTPase cycle	5
RHOBTB GTPase Cycle	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
disulfide oxidoreductase activity	1
catalytic activity, acting on a protein	1
oxidoreductase activity, acting on a sulfur group of donors	1
intracellular protein-containing complex	1
endopeptidase complex	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

1434 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TXNL1	PSMD14	O00487	876
TXNL1	PSMD4	P55036	821
TXNL1	TP53I11	O14683	772
TXNL1	DAZAP2	Q15038	763
TXNL1	NFU1	Q9UMS0	762
TXNL1	AMY1B	P04745	740
TXNL1	PPP1R3C	Q9UQK1	720
TXNL1	AMY2A	P04746	712
TXNL1	TXNDC17	Q9BRA2	688
TXNL1	HHEX	Q03014	681
TXNL1	IGLL5	B9A064	678
TXNL1	ADRM1	Q16186	631
TXNL1	PRDX1	P35703	625
TXNL1	EPM2A	O95278	609
TXNL1	AMY2B	P19961	588

IntAct

69 interactions, top by confidence:

A	B	Type	Score
UCHL5	PSMD11	psi-mi:“MI:0914”(association)	0.840
PSMB2	PSMD11	psi-mi:“MI:0914”(association)	0.730
PSMD2	PSMD11	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
PSMD14	PSMD11	psi-mi:“MI:0914”(association)	0.650
USP14	PSMD11	psi-mi:“MI:0914”(association)	0.530
TXNL1		psi-mi:“MI:0915”(physical association)	0.490
TXNL1	GOT1	psi-mi:“MI:0915”(physical association)	0.400
TXNL1	HSPB1	psi-mi:“MI:0915”(physical association)	0.370
Psmd6	MIF4GD	psi-mi:“MI:0914”(association)	0.350
PSMC1	ZNF561	psi-mi:“MI:0914”(association)	0.350
UBE3A	TXNL1	psi-mi:“MI:0914”(association)	0.350
MAPT	POTEF	psi-mi:“MI:0914”(association)	0.350
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
PRNP	WDR91	psi-mi:“MI:0914”(association)	0.350
HTRA4	PSMD12	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
PSMC4	PSMD1	psi-mi:“MI:0914”(association)	0.350
SPANXN4	UBA6	psi-mi:“MI:0914”(association)	0.350
FAM24B	SHTN1	psi-mi:“MI:0914”(association)	0.350
SDC1	ARVCF	psi-mi:“MI:0914”(association)	0.350
WFDC9	TXNL1	psi-mi:“MI:0914”(association)	0.350
CACYBP	VPS37C	psi-mi:“MI:0914”(association)	0.350
CACYBP	PSMD11	psi-mi:“MI:0914”(association)	0.350
ZFAND1	PSMD11	psi-mi:“MI:0914”(association)	0.350

BioGRID (274): TXNL1 (Two-hybrid), TXNL1 (Affinity Capture-RNA), CORO1B (Co-fractionation), DHX9 (Co-fractionation), LSM7 (Co-fractionation), SFN (Co-fractionation), TXNL1 (Co-fractionation), TXNL1 (Affinity Capture-MS), TXNL1 (Proximity Label-MS), TXNL1 (Affinity Capture-MS), TXNL1 (Affinity Capture-MS), TXNL1 (Affinity Capture-MS), TXNL1 (Proximity Label-MS), TXNL1 (Affinity Capture-MS), TXNL1 (Affinity Capture-MS)

ESM2 similar proteins: A2VE21, G3GTP0, O02485, O43396, O43747, O81742, P09874, P11103, P18493, P22892, P26446, P27008, P31669, P49917, P53620, Q29L80, Q4AEF8, Q4HYB8, Q58DV0, Q5R5M2, Q5RCE3, Q5RHR0, Q5ZK01, Q66JI9, Q6DJI5, Q6DKD7, Q6NYX8, Q8BTF7, Q8BWR2, Q8CDN6, Q8X0X6, Q90YB1, Q920B9, Q920J4, Q95ZI6, Q9BRX2, Q9GZP4, Q9I8E6, Q9PUE4, Q9QXK3

Diamond homologs: A2YIW7, C9K7C5, G4NFB7, O14463, O43396, O48897, O64394, O65049, O97508, O97680, P07591, P08628, P08629, P10599, P10639, P11232, P22217, P29429, P29445, P29446, P29447, P29450, P29451, P34723, P42115, P50413, P80028, P82460, P85801, Q0D840, Q0DKF1, Q1RQI9, Q1RQJ0, Q1RQJ1, Q29L80, Q54KN7, Q5R9M3, Q5UR29, Q5WNE3, Q5XHX6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 77 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of activated PAK-2p34 by proteasome mediated degradation	10	49.7×	3e-13
AUF1 (hnRNP D0) binds and destabilizes mRNA	11	48.8×	7e-14
Regulation of ornithine decarboxylase (ODC)	10	48.5×	3e-13
Vpu mediated degradation of CD4	10	47.4×	3e-13
Autodegradation of the E3 ubiquitin ligase COP1	10	47.4×	3e-13
Ubiquitin-dependent degradation of Cyclin D	10	47.4×	3e-13
Cross-presentation of soluble exogenous antigens (endosomes)	10	45.3×	4e-13
Vif-mediated degradation of APOBEC3G	10	45.3×	4e-13

GO biological processes:

GO term	Partners	Fold	FDR
proteasome-mediated ubiquitin-dependent protein catabolic process	13	9.6×	4e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

41 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1710 predictions. Top by Δscore:

Variant	Effect	Δscore
18:56604398:T:TA	donor_gain	1.0000
18:56610986:AACT:A	donor_loss	1.0000
18:56610987:ACTTA:A	donor_loss	1.0000
18:56610988:CT:C	donor_loss	1.0000
18:56610989:T:TC	donor_loss	1.0000
18:56610990:TACT:T	donor_loss	1.0000
18:56610991:A:AC	donor_gain	1.0000
18:56610991:ACTCG:A	donor_loss	1.0000
18:56610992:C:A	donor_loss	1.0000
18:56610992:C:CC	donor_gain	1.0000
18:56610992:CT:C	donor_gain	1.0000
18:56610992:CTCGT:C	donor_gain	1.0000
18:56611095:TAT:T	acceptor_gain	1.0000
18:56614422:A:AC	donor_gain	1.0000
18:56614423:C:CC	donor_gain	1.0000
18:56614423:CA:C	donor_gain	1.0000
18:56614451:A:AC	donor_gain	1.0000
18:56614452:A:C	donor_gain	1.0000
18:56614457:A:C	donor_gain	1.0000
18:56614479:T:TA	donor_gain	1.0000
18:56614546:CCA:C	acceptor_gain	1.0000
18:56614547:C:T	acceptor_gain	1.0000
18:56614547:CA:C	acceptor_gain	1.0000
18:56614592:CTGAC:C	acceptor_gain	1.0000
18:56617999:ATTAC:A	donor_loss	1.0000
18:56618000:TTA:T	donor_loss	1.0000
18:56618001:TACCT:T	donor_loss	1.0000
18:56618002:A:C	donor_loss	1.0000
18:56618003:C:CA	donor_loss	1.0000
18:56618122:TCCAT:T	acceptor_gain	1.0000

AlphaMissense

1937 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:56611000:A:C	F278C	1.000
18:56611000:A:G	F278S	1.000
18:56611033:C:A	G267V	1.000
18:56611033:C:T	G267D	1.000
18:56611034:C:G	G267R	1.000
18:56611090:A:T	V248D	1.000
18:56614437:A:T	V241D	1.000
18:56614452:A:T	V236D	1.000
18:56614541:A:C	F206L	1.000
18:56614541:A:T	F206L	1.000
18:56614542:A:C	F206C	1.000
18:56614543:A:G	F206L	1.000
18:56616281:T:C	K176E	1.000
18:56616283:A:T	V175D	1.000
18:56616310:A:G	L166P	1.000
18:56616313:A:G	L165P	1.000
18:56618020:G:A	S159F	1.000
18:56618021:A:G	S159P	1.000
18:56618083:A:G	L138P	1.000
18:56618085:A:C	C137W	1.000
18:56618087:A:G	C137R	1.000
18:56624409:C:G	R83P	1.000
18:56624427:G:T	P77H	1.000
18:56624428:G:A	P77S	1.000
18:56624454:G:T	A68D	1.000
18:56626380:A:T	V59D	1.000
18:56626389:A:G	F56S	1.000
18:56638354:G:C	F29L	1.000
18:56638354:G:T	F29L	1.000
18:56638356:A:G	F29L	1.000

dbSNP variants (sampled 300 via entrez): RS1000050059 (18:56620578 G>A), RS1000104588 (18:56622248 T>C,G), RS1000141195 (18:56625541 G>T), RS1000147356 (18:56637727 T>C), RS1000258605 (18:56600360 G>T), RS1000301741 (18:56633218 C>A,T), RS1000369781 (18:56637952 T>C), RS1000482227 (18:56636113 T>C), RS1000508333 (18:56630634 T>C), RS1000518408 (18:56618612 C>T), RS1000577999 (18:56599020 C>T), RS1000665777 (18:56626786 AC>A), RS1000701095 (18:56636478 A>G), RS1000756482 (18:56632116 T>C,G), RS1000856464 (18:56612217 A>G)

Disease associations

OMIM: gene MIM:603049 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002682_14	Tourette’s syndrome or obsessive-compulsive disorder	4.000000e-06
GCST006479_103	Diverticular disease	9.000000e-06
GCST007001_14	Cerebrospinal AB1-42 levels in normal cognition	9.000000e-07
GCST007325_167	General risk tolerance (MTAG)	9.000000e-09
GCST007326_21	Number of sexual partners	3.000000e-08
GCST007327_168	Smoking status (ever vs never smokers)	2.000000e-10
GCST007565_191	Morning person	5.000000e-14
GCST007576_317	Chronotype	5.000000e-14

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0009959	diverticular disease
EFO:0004670	beta-amyloid 1-42 measurement
EFO:0008579	risk-taking behaviour
EFO:0004318	smoking behavior
EFO:0008328	chronotype measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295663 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.58	Kd	259.8	nM	CHEMBL5653589
6.58	ED50	259.8	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 3 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149694: Binding affinity to human TXNL1 incubated for 45 mins by Kinobead based pull down assay	kd	0.2598	uM

CTD chemical–gene interactions

55 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	4
Valproic Acid	affects expression, increases expression	4
cobaltous chloride	increases expression	2
Copper	affects binding, decreases expression, increases expression	2
Nickel	decreases expression	2
Smoke	decreases expression	2
Tobacco Smoke Pollution	increases methylation, increases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
beta-Naphthoflavone	increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	increases expression	1
bisphenol F	increases expression	1
LGM2605	increases reaction, increases expression	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
sodium arsenate	decreases expression	1
trichostatin A	increases expression	1
beta-lapachone	increases expression	1
arsenite	decreases reaction, decreases expression, increases degradation, affects binding	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
ochratoxin A	increases expression	1
potassium chromate(VI)	decreases expression	1
cupric chloride	increases expression	1
epigallocatechin gallate	decreases expression	1
microcystin RR	decreases expression	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases reaction, increases degradation	1
tebuconazole	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118662	Binding	Binding affinity to TXNL1 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3KE	Abcam HEK293T TXNL1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.